GELS
Gelteq Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · AU
$0.43
−3.50%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 280.3K | 165.6K | — | 79.8K | 147.5K |
| Cost of Revenue | 115.4K | — | — | 48.9K | 94.9K |
| Gross Profit | 164.9K | 165.6K | — | 30.9K | 52.7K |
| Operating Expenses | |||||
| R&D Expense | 698.9K | 628.6K | 276.1K | 665.0K | 529.0K |
| SG&A Expense | 3.4M | 2.2M | 1.3M | 1.7M | 1.5M |
| General & Admin Expense | 2.1M | 2.0M | 1.2M | 1.5M | 1.5M |
| Selling & Marketing Expense | 1.0M | 204.1K | 18.2K | 166.9K | 68.4K |
| Other Expenses | 2.4M | 2.8M | 1.4M | 770.2K | 1.2M |
| Total Operating Expenses | 6.5M | 5.7M | 2.9M | 3.1M | 3.2M |
| Cost and Expenses | 6.6M | 5.7M | 2.9M | 3.2M | 3.3M |
| Operating Income (EBIT) | (6.4M) | (5.5M) | (2.9M) | (3.1M) | (3.2M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 902.1K | 1.9M | 585.1K | 403.5K | 174.5K |
| Net Interest Income | (2.2M) | (1.9M) | (600.2K) | (404.1K) | (175.6K) |
| Other Non-Op Income/Expense | (724.3K) | (1.1M) | (600.2K) | (404.1K) | (175.6K) |
| Non-Operating Income (excl Interest) | 207.2K | (744.7K) | 15.1K | 548.00 | 1.1K |
| EBT (Pre-Tax Income) | (7.1M) | (6.6M) | (3.5M) | (3.5M) | (3.4M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (7.1M) | (6.6M) | (3.5M) | (3.5M) | (3.4M) |
| Earnings from Cont. Ops | (7.1M) | (6.6M) | (3.5M) | (3.5M) | (3.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (7.1M) | (6.6M) | (3.5M) | (3.5M) | (3.4M) |
| Per Share | |||||
| Basic EPS | ($0.70) | $0.00 | $0.00 | ($0.37) | ($0.36) |
| Diluted EPS | ($0.70) | $0.00 | $0.00 | ($0.37) | ($0.36) |
| Revenue Per Share | $0.03 | $0.02 | $0.00 | $0.01 | $0.02 |
| Shares | |||||
| Basic Shares Outstanding | 10.4M | 10.0M | 9.4M | 9.4M | 9.4M |
| Diluted Shares Outstanding | 10.5M | 10.0M | 9.4M | 9.4M | 9.4M |
| Profitability Metrics | |||||
| EBITDA | (5.3M) | (3.5M) | (1.8M) | (1.9M) | (2.0M) |
| D&A | 1.2M | 1.3M | 1.2M | 1.2M | 1.2M |
| EBIT | (6.6M) | (4.8M) | (3.0M) | (3.1M) | (3.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025